830 related articles for article (PubMed ID: 34578269)
1. SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants.
Rotondo JC; Martini F; Maritati M; Mazziotta C; Di Mauro G; Lanzillotti C; Barp N; Gallerani A; Tognon M; Contini C
Viruses; 2021 Aug; 13(9):. PubMed ID: 34578269
[TBL] [Abstract][Full Text] [Related]
2. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.
Arashkia A; Jalilvand S; Mohajel N; Afchangi A; Azadmanesh K; Salehi-Vaziri M; Fazlalipour M; Pouriayevali MH; Jalali T; Mousavi Nasab SD; Roohvand F; Shoja Z;
Rev Med Virol; 2021 May; 31(3):e2183. PubMed ID: 33594794
[TBL] [Abstract][Full Text] [Related]
3. Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021.
Bui NN; Lin YT; Huang SH; Lin CW
Infect Genet Evol; 2022 Jan; 97():105164. PubMed ID: 34848355
[TBL] [Abstract][Full Text] [Related]
4. Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants.
Chakraborty C; Sharma AR; Bhattacharya M; Agoramoorthy G; Lee SS
mBio; 2021 Aug; 12(4):e0114021. PubMed ID: 34465019
[TBL] [Abstract][Full Text] [Related]
5. The variants of SARS-CoV-2 and the challenges of vaccines.
Han X; Ye Q
J Med Virol; 2022 Apr; 94(4):1366-1372. PubMed ID: 34890492
[TBL] [Abstract][Full Text] [Related]
6. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
7. COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era.
Volkan E
Mol Biotechnol; 2021 Oct; 63(10):885-897. PubMed ID: 34145550
[TBL] [Abstract][Full Text] [Related]
8. Spread of Gamma (P.1) Sub-Lineages Carrying Spike Mutations Close to the Furin Cleavage Site and Deletions in the N-Terminal Domain Drives Ongoing Transmission of SARS-CoV-2 in Amazonas, Brazil.
Naveca FG; Nascimento V; Souza V; Corado AL; Nascimento F; Silva G; Mejía MC; Brandão MJ; Costa Á; Duarte D; Pessoa K; Jesus M; Gonçalves L; Fernandes C; Mattos T; Abdalla L; Santos JH; Martins A; Chui FM; Val FF; de Melo GC; Xavier MS; Sampaio VS; Mourão MP; Lacerda MV; Batista ÉLR; Magalhães ALÁ; Dábilla N; Pereira LCG; Vinhal F; Miyajima F; Dias FBS; Dos Santos ER; Coêlho D; Ferraz M; Lins R; Wallau GL; Delatorre E; Gräf T; Siqueira MM; Resende PC; Bello G;
Microbiol Spectr; 2022 Feb; 10(1):e0236621. PubMed ID: 35196783
[TBL] [Abstract][Full Text] [Related]
9. The variants question: What is the problem?
Zella D; Giovanetti M; Benedetti F; Unali F; Spoto S; Guarino M; Angeletti S; Ciccozzi M
J Med Virol; 2021 Dec; 93(12):6479-6485. PubMed ID: 34255352
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 vaccine breakthrough infections.
Gupta RK; Topol EJ
Science; 2021 Dec; 374(6575):1561-1562. PubMed ID: 34941414
[TBL] [Abstract][Full Text] [Related]
11. Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs.
Thura M; Sng JXE; Ang KH; Li J; Gupta A; Hong JM; Hong CW; Zeng Q
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34519332
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8
Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T
Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
[TBL] [Abstract][Full Text] [Related]
14. Evolutionary study of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an emerging coronavirus: Phylogenetic analysis and literature review.
Tabibzadeh A; Esghaei M; Soltani S; Yousefi P; Taherizadeh M; Safarnezhad Tameshkel F; Golahdooz M; Panahi M; Ajdarkosh H; Zamani F; Karbalaie Niya MH
Vet Med Sci; 2021 Mar; 7(2):559-571. PubMed ID: 33210477
[TBL] [Abstract][Full Text] [Related]
15. Variants of SARS-CoV-2, their effects on infection, transmission and neutralization by vaccine-induced antibodies.
Wahid M; Jawed A; Mandal RK; Dailah HG; Janahi EM; Dhama K; Somvanshi P; Haque S
Eur Rev Med Pharmacol Sci; 2021 Sep; 25(18):5857-5864. PubMed ID: 34604978
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 variants, spike mutations and immune escape.
Harvey WT; Carabelli AM; Jackson B; Gupta RK; Thomson EC; Harrison EM; Ludden C; Reeve R; Rambaut A; ; Peacock SJ; Robertson DL
Nat Rev Microbiol; 2021 Jul; 19(7):409-424. PubMed ID: 34075212
[TBL] [Abstract][Full Text] [Related]
17. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
[TBL] [Abstract][Full Text] [Related]
18. Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients.
Carreño JM; Alshammary H; Singh G; Raskin A; Amanat F; Amoako A; Gonzalez-Reiche AS; van de Guchte A; Study Group P; Srivastava K; Sordillo EM; Sather DN; van Bakel H; Krammer F; Simon V
EBioMedicine; 2021 Nov; 73():103626. PubMed ID: 34688034
[TBL] [Abstract][Full Text] [Related]
19. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
Elife; 2021 Oct; 10():. PubMed ID: 34636722
[TBL] [Abstract][Full Text] [Related]
20. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]